Last reviewed · How we verify
bupivacaine, levobupivacaine
Bupivacaine and levobupivacaine, marketed by National Taiwan University Hospital, are established anesthetics with a key composition patent expiring in 2028. The drugs benefit from a well-documented safety profile and extensive clinical use, positioning them as reliable options in the anesthetic market. The primary risk is the potential increase in generic competition following the 2028 patent expiry, which could erode market share and revenue.
At a glance
| Generic name | bupivacaine, levobupivacaine |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Observational Retrospective Study on Spinal Analgesia in Laparoscopic and Laparotomic Hysterectomy
- Advantage of Tramadol in Local Analgesia Post-Sternotomy (PHASE4)
- Ketamine Versus Magnesium Sulphate as Adjuvants for ESPB in Breast Cancer Surgery (PHASE2)
- Echo-guided Transverse Abdominal Plane Block (TAP) in Anterior Lumbar Arthrodesis (ALIF) (NA)
- Investigation of Antibacterial Effect of Levobupivacaine on Staphylococcus Aureus (NA)
- Effect of a Transversus Abdominis Plane Block on Wound Healing, Stress, and Immune Response After a Cesarean Delivery (NA)
- ACU_Knee: Role of Acupuncture in Knee Prosthetic Surgery (NA)
- Non-opioid Anesthesia Based on Thoracic Paravertebral Block During Laparoscopic Sleeve Gastrectomy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bupivacaine, levobupivacaine CI brief — competitive landscape report
- bupivacaine, levobupivacaine updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI